The Clinical Course of Venous Thromboembolism May Differ According to Cancer Site
Isabelle Mahé,Jean Chidiac,Laurent Bertoletti,Carme Font,Javier Trujillo-Santos,Marisa Peris,Cristina Pérez Ductor,Santiago Nieto,Elvira Grandone,Manuel Monreal,RIETE investigators,M A Aibar,J I Arcelus,A Ballaz,R Barba,M Barrón,B Barrón-Andrés,J Bascuñana,A Blanco-Molina,T Bueso,I Casado,A Culla,J de Miguel,J Del Toro,J A Díaz-Peromingo,C Falgá,C Fernández-Capitán,C Font,L Font,P Gallego,F García-Bragado,P García-Brotons,V Gómez,J González,E Grau,A Grimón,L Guirado,J Gutiérrez,G Hernández,L Hernández-Blasco,V Isern,L Jara-Palomares,M J Jaras,D Jiménez,B Lacruz,R Lecumberri,J L Lobo,L López-Jiménez,R López-Reyes,J B López-Sáez,M A Lorente,A Lorenzo,O Madridano,P J Marchena,J M Martín-Antorán,F Martín-Martos,M Monreal,M V Morales,D Nauffal,J A Nieto,S Nieto,M J Núñez,S Otalora,R Otero,B Pagán,J M Pedrajas,C Pérez,G Pérez,M L Peris,J A Porras,L Ramírez,O Reig,A Riera,A Rivas,M A Rodríguez-Dávila,V Rosa,P Ruiz-Artacho,N Ruiz-Giménez,C Ruiz-Martínez,A Sampériz,C Sala,O Sanz,S Soler,B Sopeña,I Suarez,J M Suriñach,G Tiberio,C Tolosa,J Trujillo-Santos,F Uresandi,R Valle,J Vela,J Villalta,P C Malfante,P Verhamme,P Wells,J Hirmerova,R Malý,T Tomko,E Salgado,L Bertoletti,A Bura-Riviere,D Farge-Bancel,A Hij,I Mahé,A Merah,M Papadakis,A Braester,B Brenner,I Tzoran,A Apollonio,G Barillari,G Candeloro,M Ciammaichella,P Di Micco,P Ferrazzi,E Grandone,G Lessiani,C Lodigiani,D Mastroiacovo,F Pace,M Pinelli,P Prandoni,L Rota,E Tiraferri,A Tufano,A Visonà,A Belovs,A Skride,M Moreira,J L Ribeiro,M S Sousa,M Bosevski,M Zdraveska,A Alatri,H Bounameaux,L Calanca,L Mazzolai,J C Serrano,Hervé Decousus,Abilio Reis
DOI: https://doi.org/10.1016/j.amjmed.2016.10.017
Abstract:Background: We hypothesized that the clinical course of venous thromboembolism in patients with active cancer may differ according to the specificities of primary tumor site. Aim and methods: We used data from RIETE (international registry of patients with venous thromboembolism) to compare the clinical venous thromboembolism-related outcomes during the course of anticoagulation in patients with one of the 4 more frequent cancers (breast, prostate, colorectal, or lung cancer). Results: As of September 2014, 3947 cancer patients were recruited, of whom 938 had breast, 629 prostate, 1189 colorectal, and 1191 lung cancer. Overall, 55% had metastatic disease (42%, 36%, 53%, and 72%, respectively). During the course of anticoagulant therapy (mean duration, 139 days), the rate of thromboembolic recurrences was similar to the rate of major bleeding in patients with breast (5.6 [95% confidence interval (CI), 3.8-8.1] vs 4.1 [95% CI, 2.7-5.9] events per 100 patient-years) or colorectal cancer (10 [95% CI, 7.6-13] vs 12 [95% CI, 9.4-15] per 100 patient-years). In contrast, in patients with prostate cancer, the rate of venous thromboembolic recurrences was half the rate of major bleeding (6.9 [95% CI, 4.4-10] vs 13 [95% CI, 9.2-17] events per 100 patient-years), whereas in those with lung cancer, the rate of thromboembolic recurrences was twofold higher than the rate of major bleeding (27 [95% CI, 22-23] vs 11 [95% CI, 8.6-15] per 100 patient-years). Conclusions: Significant differences in the clinical profile of venous thromboembolic-related outcomes were observed according to the site of cancer. These findings suggest the development of cancer-specific anticoagulant strategies as an area for further research.